Clomiphene in Men

Understand

Overview

Clomiphene citrate — sold in Poland under the brand name Clostilbegyt and known in the English-language literature as Clomid — is a selective estrogen receptor modulator (SERM), a drug originally developed and approved for treating infertility in women, where it has been used for decades to induce ovulation. In men, it is used exclusively off-label, meaning outside its approved indication, to treat secondary hypogonadism — a condition in which low testosterone results from insufficient stimulation of the testes by the hypothalamic-pituitary-gonadal (HPG) axis, rather than from damage to the testes themselves.

What sets clomiphene apart from classic testosterone replacement therapy (TRT) is not a pharmacological nuance of interest only to endocrinologists — it's a fundamental mechanistic difference with very practical consequences. TRT supplies testosterone from outside the body, which does raise blood levels, but through negative feedback it also suppresses the pituitary's own secretion of LH and FSH, shutting down the testes' natural production of both testosterone and sperm. Clomiphene works in essentially the opposite direction: it blocks estrogen receptors in the hypothalamus, so the brain 'doesn't see' circulating estrogen and misreads the situation as a deficiency of sex hormones, increasing the release of GnRH and, in turn, LH and FSH from the pituitary. Higher LH stimulates the Leydig cells in the testes to increase their own, endogenous testosterone production — the testes don't atrophy, the HPG axis stays active, and spermatogenesis, which depends on high intratesticular testosterone, can in theory be preserved far better than during standard TRT.

It's precisely this feature — no suppression of natural hormone production and the potential preservation of fertility — that makes clomiphene a option considered particularly for younger men with secondary hypogonadism who plan to have children in the future or want to avoid the noticeable testicular shrinkage associated with TRT. Here, though, a distinction needs to be introduced right away that is the core of this entry and that popular sources often blur: the evidence that clomiphene effectively raises testosterone, LH and FSH and relieves hypogonadism symptoms is solid and consistent across multiple studies. The evidence that clomiphene actually improves fertility outcomes — specifically the pregnancy rate — is considerably weaker, and in the most current, 2025 meta-analysis, statistically not significant. In other words: clomiphene is good at 'fixing' a hormone test result, but whether that hormonal improvement actually translates into a higher chance of conceiving has not been clearly established — a distinction worth knowing before making a decision, not after.

Clinical studies provide concrete numbers here. In one long-term study (Moskovic et al., 2012), 46 patients saw baseline testosterone of 228 ng/dL rise to 612 ng/dL after one year of therapy and remain stable through 3 years of follow-up, alongside significant improvement in femoral neck and lumbar spine bone density and no reported adverse events. In another study (Katz et al., 2012), covering 86 younger men (mean age 29), most of whom were seeking treatment specifically to preserve fertility, mean treatment duration was 19 months, and testosterone and gonadotropins rose significantly with no major adverse events — the authors described clomiphene as an effective, safe alternative to exogenous testosterone in this younger, fertility-focused population. A head-to-head comparison with TRT (Ramasamy et al., 2014), meanwhile, showed that the median total testosterone achieved on clomiphene (504 ng/dL) was lower than what's typically achieved with testosterone injections, but patient-reported satisfaction, measured via the qADAM questionnaire, was comparable across the clomiphene, injection, and gel groups.

It's also worth mentioning the Guay et al. (2003) study, which followed 178 men with secondary hypogonadism and erectile dysfunction treated with clomiphene for 4 months — sexual function improved in 75% of patients and remained unchanged in the other 25%, even though LH and free testosterone rose significantly in almost everyone. That's a telling, honest result: a hormonal improvement alone doesn't guarantee a clinical improvement for every patient, and in this study the clinical response correlated with age and comorbidity burden — not every man with a higher testosterone level will feel a real improvement in well-being or sexual function.

On fertility specifically, the data are, as noted, considerably weaker than for the hormonal effect. A 2007 Cochrane review (Vandekerckhove et al.) analyzing 10 RCTs in 738 men found that anti-estrogens (including clomiphene) raised testosterone, but the pregnancy rate rose only from 12.5% in the control group to 15.4% in the treated group — a difference that was not statistically significant. Importantly, and often overlooked: this Cochrane review was subsequently WITHDRAWN from the Cochrane database, so it should not be cited as a currently standing position of that organization — it's mentioned here purely as part of the research history on this question, with its status clearly noted. The most current, still-standing data come from a 2025 meta-analysis (Khashaba et al.) covering 10 RCTs: the pregnancy rate was 10.4% on clomiphene versus 7.1% on placebo, odds ratio 1.30 (95% CI 0.27-6.17), p=0.74 — again, not statistically significant. This is the most current and most sobering word on the subject: although clomiphene effectively raises testosterone and gonadotropins, the evidence that this translates into a higher pregnancy rate for couples dealing with unexplained male infertility remains insufficient today.

That leads to a key practical takeaway: clomiphene is worth considering as a way to treat secondary hypogonadism while preserving testicular function and without suppressing the body's own hormonal axis — not as a guaranteed, evidence-proven 'fertility drug.' That distinction matters especially for couples counting on a concrete, measurable improvement in their chances of conceiving, rather than just a better blood test result for the man.